COF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Capital One Financial Corp (COF) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock's technical indicators are bearish, options sentiment leans negative, and recent news includes potential securities fraud investigations. While the company's financial performance in Q4 2025 was strong, the stock faces headwinds from higher expenses and dilution from the Brex acquisition. Analyst ratings remain positive overall, but price targets have been lowered. Given the balanced trading activity by Congress members and lack of strong proprietary trading signals, holding off on a purchase is recommended.
The technical indicators for COF are bearish. The MACD is negative and contracting, the RSI is neutral at 37.379, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 198.934, with key support at 189.957 and resistance at 207.911.
Strong Q4 2025 financial performance with revenue up 54.22% YoY, net income up 101.96% YoY, and EPS up 22.10% YoY.
Analysts maintain overall positive ratings, with Buy and Overweight ratings from multiple firms.
Congress members have made significant purchase transactions in the last 90 days, indicating some confidence in the stock.
Securities fraud investigation by Pomerantz LLP, which could impact investor sentiment.
Higher expenses and dilution from the Brex acquisition, which have led to lowered analyst price targets.
Bearish technical indicators and options sentiment.
Neutral trading trends from hedge funds and insiders.
Capital One's Q4 2025 financials were strong, with revenue increasing to $15.1 billion (up 54.22% YoY), net income rising to $2.06 billion (up 101.96% YoY), and EPS growing to $3.26 (up 22.10% YoY). However, gross margin remained unchanged. The Brex acquisition is expected to strengthen the company's product suite but has introduced near-term dilution and higher expenses.
Analysts maintain a generally positive outlook on COF, with Buy and Overweight ratings from firms like Truist, Barclays, and Wells Fargo. However, price targets have been lowered across the board, reflecting concerns about higher expenses and the dilution impact of the Brex acquisition. The stock is seen as a long-term play, with potential benefits from its expanded product suite and improving credit trends.
